| Course | NU675 PMHNP Diagnosis and Management Across the Lifespan II |
|---|---|
| Unit | Unit 3 |
| Paper type | Medication switch plan |
| Length | About 850 words, 6 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | MSN |
| Updated | September 2026 |
Free sample paper for NU675 Unit 3
Half the Usual Pace Because of One Interaction: A Medication Switch Plan From Valproate to Lamotrigine for a 31-Year-Old Planning a Pregnancy
[Student Name]
Purdue University Global
NU675: PMHNP Diagnosis and Management Across the Lifespan II
Unit 3 Medication Switch Plan
[Instructor Name]
[Date]
The patient is composite; doses, dates and levels are bracketed.
Why Switch
Ms. [L.] has bipolar I disorder with two manic episodes, the last [three] years ago, and one depressive episode. She has been stable on valproate [1,000] mg daily, level [72] mcg/mL. She and her partner hope to conceive in about [twelve] months. She currently uses condoms.
Valproate is the anticonvulsant most strongly associated with harm to a developing fetus. In a large international pregnancy registry, the rate of major congenital malformations was significantly higher with valproate at all doses than with lamotrigine at doses of [325] mg a day or less (Tomson et al., 2018). In a prospective study of children exposed in pregnancy, fetal valproate exposure had dose-dependent associations with reduced cognitive abilities at age six (Meador et al., 2013). The switch is not optional for a woman planning a pregnancy on valproate; the only question is how to make it without a relapse.
Lamotrigine is a reasonable replacement because her illness has more depressive than manic burden in recent years and because, in a maintenance trial, lamotrigine delayed intervention for mood episodes compared with placebo, with a stronger effect against depression than mania (Calabrese et al., 2003). Its weaker protection against mania is the main risk of the switch, and the plan watches for it.
Before Starting
1. Contraception: switch from condoms to a copper intrauterine device before the change begins, because valproate remains teratogenic until it is stopped and because estrogen-containing contraceptives lower lamotrigine levels.
2. Folic acid [4] mg daily from now, since she may conceive.
3. Baseline: mood ratings, weight, and a discussion of rash.
4. Relapse signature from her previous episodes: sleeping less than [six] hours for two nights, spending unusually, and talking faster. Her partner knows these signs.
The Schedule
Because valproate inhibits the breakdown of lamotrigine and roughly doubles its levels, lamotrigine is started at half the usual dose and increased at half the usual rate while valproate continues. A faster schedule raises the risk of serious rash, including Stevens-Johnson syndrome.
1. Weeks 1 and 2: lamotrigine [25] mg every other day. Valproate [1,000] mg daily.
2. Weeks 3 and 4: lamotrigine [25] mg daily. Valproate unchanged.
3. Week 5: lamotrigine [50] mg daily.
4. Week 6: lamotrigine [100] mg daily, the usual target while taking valproate.
5. Weeks 7 to 10: reduce valproate by [250] mg every [two] weeks, from [1,000] mg to zero.
6. As valproate falls, lamotrigine levels will fall too, so lamotrigine is increased in steps to [200] mg daily over the same weeks, following the label's instructions for withdrawing valproate.
7. Week 12: lamotrigine [200] mg daily alone. Review.
Monitoring During the Switch
1. Rash: she will stop lamotrigine and call the same day if a rash appears, especially with fever, mouth sores or blistering.
2. Mood: weekly phone check during weeks 5 to 12, and a clinic visit at week [8] and week [12].
3. Relapse: if two signs of her relapse signature appear, valproate reduction pauses and she is seen within [48] hours.
4. Levels: a lamotrigine level at week [12] as a baseline for pregnancy, when levels are expected to fall and doses may need adjustment.
After the Switch
She should be stable on lamotrigine alone for at least [six] months before trying to conceive. A preconception visit with her obstetric clinician will plan monitoring of lamotrigine levels in pregnancy and after delivery.
Explaining the Switch to Her
Before she agreed, the reasons were set out in everyday language. Valproate has kept her well, and the reason to change is not that it has failed but that it carries a higher risk to a baby than the alternatives. Lamotrigine protects well against depression and less well against mania, so the team will watch closely for the early signs of a high. The new medicine starts slowly because the old one raises its level in the blood, and starting too fast can cause a serious rash; any rash is a reason to call the same day. The switch will take about three months, and trying to conceive should wait until she has been stable on the new medicine for about six more. She asked whether she could simply stop valproate when she became pregnant; she was told that stopping a mood stabilizer suddenly risks a relapse at the worst time, and that the malformations linked to valproate occur early, often before a pregnancy is known. She and her partner chose to proceed.
What Would Change the Plan
A manic relapse would pause the switch and prompt discussion of other options with lower reproductive risk. A serious rash would stop lamotrigine immediately. If she became pregnant during the switch, valproate would be stopped as quickly as safely possible and she would be seen urgently.
References
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., & DeVeaugh-Geiss, J. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. The Journal of Clinical Psychiatry, 64(9), 1013-1024. https://doi.org/10.4088/JCP.v64n0906
Meador, K. J., Baker, G. A., Browning, N., Cohen, M. J., Bromley, R. L., Clayton-Smith, J., Kalayjian, L. A., Kanner, A., Liporace, J. D., Pennell, P. B., Privitera, M., & Loring, D. W. (2013). Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study. The Lancet Neurology, 12(3), 244-252. https://doi.org/10.1016/S1474-4422(12)70323-X
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Perucca, E., Sabers, A., Thomas, S. V., Vajda, F., Faravelli, F., Pantaleoni, C., Robert-Gnansia, E., Cabral-Lim, L., Čebular, B., De Marinis, A., Kälviäinen, R., Khomeriki, K., Kiteva-Trencevska, G., Kochen, S., . . . Zarifi-Oskoie, M. (2018). Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry. The Lancet Neurology, 17(6), 530-538. https://doi.org/10.1016/S1474-4422(18)30107-8
What the NU675 Unit 3 assignment asks for
The Unit 3 assignment asks you to plan a switch from one psychotropic medication to another for a specific reason. Prompts usually require the reason for switching with evidence, the choice of the new agent, a week-by-week cross-titration schedule that accounts for interactions, monitoring during the switch, and what would change the plan. Expect to write three to five pages. Faculty reward schedules that explain why each step is paced as it is, rather than presenting doses without reasons, and that name the specific risks of the transition. Addressing the patient's life circumstances, here contraception and pregnancy timing, shows the plan was built for this person rather than copied from a reference table.
How this NU675 Unit 3 example is built
The plan explains why the switch is needed, citing malformation rates from the EURAP registry and cognitive outcomes from the NEAD study, with a highlighted sentence on why it is not optional. It justifies lamotrigine with the Calabrese maintenance trial and names its weaker protection against mania. A pre-switch section sets contraception, folic acid, baselines and her relapse signature. The schedule runs week by week, with the valproate interaction explained. Monitoring covers rash, mood, relapse and a lamotrigine level for pregnancy. A section records how the switch was explained to her and her question about stopping at conception, and a final section lists what would pause or change the plan.
NU675 Unit 3 rubric: what earns full points
Switch plans are usually graded on the justification for switching, the choice of new agent, the accuracy and logic of the schedule, monitoring and patient involvement. Justification earns full points when the risk of the current drug is supported by evidence and tied to the patient's plans. The agent row rewards a choice matched to her illness pattern, with its weaknesses named. The schedule is judged on correct handling of the interaction and of rash risk. Monitoring points go to specific signs with specific responses and timelines. Patient involvement is scored on whether her questions, preferences and consent are recorded in the plan itself, not only mentioned in passing.
NU675 Unit 3 help from the desk
The most dangerous error in this switch is starting lamotrigine at the usual dose while valproate is still being taken, which raises the risk of serious rash. Another is forgetting to raise the lamotrigine dose as valproate is withdrawn, which can leave her undertreated. Students often overlook contraception during the switch, or recommend an estrogen-containing method that lowers lamotrigine levels. Some plans stop valproate before lamotrigine is established. Others omit folic acid for a woman planning pregnancy. And a plan that does not say what happens if she conceives during the switch leaves the most urgent scenario without guidance. Keep the week-by-week schedule on one page so a covering clinician can read it quickly.
Get an NU675 Unit 3 example written to your instructions
Tell us the two agents your NU675 Unit 3 case switches between, or that the choice is yours, and forward the case, history included, with the rubric. The first custom plan is free within 24-48h, laid out in phases with a watch column and a pause rule for each, and every figure bracketed. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU675 papers and MSN samples
- NU675 Unit 1: Stopping an Antidepressant Post
- NU675 Unit 2: Antipsychotic Continuation Decision
- NU675 Unit 4: Polypharmacy Review
- NU675 Unit 5: Seminar Reflection
- NU675 Unit 6: Relapse Prevention Plan
- NU675 Unit 7: Metabolic Monitoring Brief
- NU675 Unit 8: Discontinuation Case Analysis
- NU675 Unit 9: Recovery Goals Statement
- NU675 Unit 10: Year-long Case Review
- NU674 Unit 3: HPI With a Seasonal Pattern
- NU673 Unit 3: Kratom Screening Write-Up
- NU672 Unit 3: Supervision Note on Self-Disclosure
- MN501 Unit 3: Scope of Practice Review
NU675 Unit 3 questions, answered
How long should a switch plan take?
As long as the drugs involved require, which the plan should explain rather than assert. Interactions, the need to titrate slowly and the risk of losing protection during the overlap all set the pace. Present the timeline in phases with conditions for moving on, and note that a phase can be extended if symptoms appear. Keep specific figures bracketed as composite.
Should the plan consider stopping medication before pregnancy instead of switching?
It should mention it, since some patients ask, and explain why it was or was not chosen. For bipolar I disorder with past mania, stopping carries a substantial risk of relapse, and the postpartum period adds more. Weigh that against fetal exposure, cite the sources you use, and involve the obstetric clinician in the reasoning.
What makes a watch list specific enough?
Tie each item to a phase and a response. Rash during titration means same-day review; two nights of little sleep as the older drug is withdrawn means a call to the prescriber. Draw early signs from the documented history where the case supplies it, since a generic list of mania symptoms tells the reader little about this person.
Where can I find a free NU675 Unit 3 sample paper?
This page gives the full NU675 Unit 3 medication switch plan, with the reasons for switching, the week-by-week schedule, monitoring, what she was told and what would change the plan, plus three references. A switch plan for your own patient can be drafted to your prompt.
Why is lamotrigine started so slowly in NU675 Unit 3?
Valproate slows the breakdown of lamotrigine and roughly doubles its levels, so lamotrigine starts at half the usual dose and is increased at half the usual rate while valproate continues. A faster schedule raises the risk of serious rash, including Stevens-Johnson syndrome.